Paramètres des cookies

Ce site web utilise des cookies à des fins d'optimisation et d'analyse statistique et pour afficher des annonces personnalisées. Pour plus d'informations, veuillez svp. consulter notre déclaration de confidentialité sur la protection de données personnelles.

Servier

Servier receives a positive CHMP opinion for Tibsovo® in IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma (CCA) patients

24.02.2023 – 13:11

Paris (ots/PRNewswire)

  • Tibsovo® (ivosidenib tablets) is the first IDH1 inhibitor recommended for approval in Europe
  • The positive CHMP opinion is based on clinical data from the AGILE (in AML) and ClarIDHy (in CCA) studies

Servier, a global pharmaceutical company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting a marketing authorization for Tibsovo® (ivosidenib tablets) - an inhibitor of the mutated isocitrate dehydrogenase-1 (IDH1) enzyme - for two indications:

  • in combination with azacitidine, for the treatment of adult patients with newly diagnosed IDH1-mutated Acute Myeloid Leukemia and not eligible for standard induction chemotherapy,
  • in monotherapy, for the treatment of adult patients with locally advanced or metastatic IDH1-mutated Cholangiocarcinoma, previously treated by at least one prior line of systemic therapy.

Claude Bertrand, Executive Vice President R&D of Servier, said: "The positive CHMP opinion is a further step towards the availability, in the European Union, of Tibsovo® which is the first IDH1 inhibitor to be recommended for approval in Europe for patients with Acute Myeloid Leukemia and Cholangiocarcinoma for whom therapeutic options are very limited. Tibsovo® is an illustration of the Group's transformation and commitment in oncology which focuses its research on hard-to-treat cancers with the development of targeted therapies being a promising path for patients."

The positive CHMP opinion is based on clinical data from the AGILE (AML) and ClarIDHy (CCA) studies.

The CHMP's positive opinion on Tibsovo® in IDH1 mutated AML and CCA patients will be referred to the European Commission (EC) which will deliver a final decision in the coming months. The decision will be applicable to all 27 EU member states plus Iceland, Norway, Northern Ireland and Liechtenstein.

PDF - https://mma.prnewswire.com/media/2009347/PR___Servier.pdf

Logo - https://mma.prnewswire.com/media/1914957/Servier_Logo.jpg

Contact: presse@servier.com

View original content to download multimedia: https://www.prnewswire.co.uk/news-releases/servier-receives-a-positive-chmp-opinion-for-tibsovo-in-idh1-mutated-acute-myeloid-leukemia-aml-and-cholangiocarcinoma-cca-patients-301755348.html

Contact:

Tel. +33 (0)1 55 72 40 21

Lieux dans ce communiqué
Plus de actualités: Servier
Plus de actualités: Servier
Tous Actualités Tous
  • 02.02.2023 – 07:30

    Servier full year 2021/22 results confirm the transformation trajectory of the Group

    Paris (ots/PRNewswire) - - Consolidated sales revenue of €4.876 billion, up 9.8% (+6.6% at CERi), driven by strong growth in international sales - Sales revenue for brand-name medicines reached €3.694 billion, up 12.5% (+8.9% at CERi), and €1.182 billion for generics, up 2.0% (stable at CERi) - Important developments in oncology to address high unmet medical ...

    plus
  • 06.10.2022 – 07:30

    Servier unveils its 2030 ambition and reveals a new visual identity

    Paris (ots/PRNewswire) - - A new ambition by 2030 to accelerate its transformation dynamic - A visual identity, a marker of the successful transformation of the Group, its ambitions and its renewal Servier today unveils its 2030 ambition as well as a new visual identity that reflects the transformation undertaken by the Group, bringing visible results. The Group intends to accelerate its transformation dynamics in order ...

    plus
  • 18.01.2022 – 13:01

    Servier Group Reports Financial Year 2020/2021 Annual Results, R&D Strategy and Pipeline

    Paris (ots/PRNewswire) - - Consolidated revenue of €4.725 billion, up +4.3% at constant rates (+0.8% at current rates) - Revenue for brand-name medicines of €3.306 billion +4.8% at constant rates (+0.6% at current rates) and €1.419 billion for the generics +2.9% at constant rates (+1.1% at current rates) - An accelerated oncology strategy with the acquisition of ...

    plus